- Table of Contents
We validate the specificity of these antibodies to Nhej1 by testing them on tissues known to express Nhej1 positively and negatively. Browse below to find the Nhej1 antibody that suites your experiment. We have 7 of these antibodies and many publications and validation images.
If you cannot find antibodies that fit your needs, contact us for making custom antibodies. We have a full suite of custom antibody services covering from research to diagnostic and therapeutic applications.
Facts about Non-homologous end-joining factor 1.
It may act in concert with XRCC6/XRCC5 (Ku) to stimulate XRCC4-mediated joining of blunt ends and several kinds of mismatched ends that are noncomplementary or partially complementary (PubMed:17360556). Binds DNA in a length-dependent way (By similarity).
Cernunnos; non-homologous end-joining factor 1; nonhomologous end-joining factor 1; Protein cernunnos; XLFFLJ12610; XRCC4-like factor
This article examines Steven Boster's research, biography, and writings. It examines the work and history of this biomedical entrepreneur. The NHEJ1 marker, which is a protein expressed by E.coli containing His–Tag, is a protein. Its sequence domain number is 1-224aa. It can be stored at temperatures between +2degC - +8degC for up to a week. NHEJ1 should be kept at -20degC- -80degC for extended storage. It should be kept at between -20 and 80 degrees Celsius, but avoid repeated freeze-thaw cycles. Boster scientists sharing their results can be eligible for product credits. These credits can be used by all Boster scientists in addition to their own research centers and institutions.
Steven Boster, an American biotech entrepreneur founded PicoKine. PicoKine was the most prominent provider of high-sensitivity ELISA test kits. Boster developed his first product in 1993. His business grew quickly to become the largest Chinese catalog antibody company by the late 1990s. PicoKine(tm), which is his unique ELISA platform uses proprietary trade secrets to deliver ultrasensitive ELISA Kits, has been patented.
Don Boster was killed in an automobile accident on June 26, 2022 in Madison, Wisconsin. Born in Joliet, IL, Boster was a successful retail sales manager for many years and was a U.S. Army veteran. He was also an active member of the Concordia Hall at Staunton. His surviving family includes his two daughters Crystal Boster- and Natosha Poeck, 6 grandchildren and 4 brothers Jack Boster- and Sandra Blanton-. He also had many nieces.
His recent research with NHEJ1 markers has revealed that this gene encodes a protein, which is crucial in repairing damaged DNA. Mutations in NHEJ genes disrupt the development of the immune system, impairing B and T cell maturation. SCID is often a neonatal disease characterized both by severe bacterial infections and opportunistic diseases.
He recently discovered that PTEN regulates NHEJ via its interaction with PCAF, CBP. This suggests a new functional role for the PTEN. This study further identified PTEN as a biomarker of impaired NHEJ. Further research is needed before NHEJ1 can be used for diagnostic purposes. The NHEJ1 markers have many potential applications in advancing understanding of neoplasia.
The study focuses on a genetic marker called NHEJ1. This gene is involved in DNA repair. Mutations in it can lead to defects in the immune system or T-cell maturation. SCID usually presents early in life with severe respiratory or bacterial infections. The findings have implications for the treatment of this condition and may lead to new therapeutic options. His research on NHEJ1 will aid doctors in determining which genes to target for SCID.
The researchers found that NHEJ1 protein levels in cancer tissues were significantly lower than those in normal controls. Researchers also found that tumors expressing high levels NHEJ1 protein had less aggressive disease. Therefore, this marker may be an effective therapeutic target for colon cancer. The findings suggest PAXX may be an emerging therapeutic target. His research on NHEJ1 markers is a promising step in colon cancer research.